Advertisement
BIOA vs NBIX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a Hold and NBIX is a StrongBuy.
BIOA's Indicator enters downward trend
The Aroon Indicator for BIOA entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 73 similar instances where the Aroon Indicator formed such a pattern. In 65 of the 73 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIOA's RSI Oscillator exited the oversold zone, 6 of 7 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 21 of 28 cases where BIOA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for BIOA just turned positive on October 20, 2026. Looking at past instances where BIOA's MACD turned positive, the stock continued to rise in 15 of 18 cases over the following month. The odds of a continued upward trend are 83%.
Following a +14.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOA advanced for three days, in 98 of 120 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BIOA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.675) is normal, around the industry mean (11.138). P/E Ratio (-2.305) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (29.762) is also within normal values, averaging (178.797).
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. BIOA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
NBIX sees its Stochastic Oscillator climbs out of oversold territory
On October 19, 2026, the Stochastic Oscillator for NBIX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 57 instances where the indicator left the oversold zone. In 41 of the 57 cases the stock moved higher in the following days. This puts the odds of a move higher at over 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Oscillator exited the oversold zone, 18 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 20, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 36 of 53 cases over the following month. The odds of a continued upward trend are 68%.
Following a +4.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 222 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In 43 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for NBIX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.889) is normal, around the industry mean (11.138). P/E Ratio (20.044) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BIOA | NBIX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 59 | |
SMR RATING 1..100 | 96 | 44 | |
PRICE GROWTH RATING 1..100 | 65 | 58 | |
P/E GROWTH RATING 1..100 | 100 | 90 | |
SEASONALITY SCORE 1..100 | 43 | 36 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIOA's Valuation (27) in the Chemicals Specialty industry is in the same range as NBIX (58) in the Biotechnology industry. This means that BIOA’s stock grew similarly to NBIX’s over the last 12 months.
NBIX's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for BIOA (100) in the Chemicals Specialty industry. This means that NBIX’s stock grew somewhat faster than BIOA’s over the last 12 months.
NBIX's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for BIOA (96) in the Chemicals Specialty industry. This means that NBIX’s stock grew somewhat faster than BIOA’s over the last 12 months.
NBIX's Price Growth Rating (58) in the Biotechnology industry is in the same range as BIOA (65) in the Chemicals Specialty industry. This means that NBIX’s stock grew similarly to BIOA’s over the last 12 months.
NBIX's P/E Growth Rating (90) in the Biotechnology industry is in the same range as BIOA (100) in the Chemicals Specialty industry. This means that NBIX’s stock grew similarly to BIOA’s over the last 12 months.
| BIOA | NBIX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 64% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 72% |
| Momentum ODDS (%) | N/A | 2 days ago 50% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 56% |
| Advances ODDS (%) | 3 days ago 82% | 3 days ago 70% |
| Declines ODDS (%) | 7 days ago 81% | 10 days ago 54% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 70% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 52% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIOA’s FA Score shows that 1 FA rating(s) are green while NBIX’s FA Score has 0 green FA rating(s).
- BIOA’s FA Score: 1 green, 4 red.
- NBIX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIOA’s TA Score shows that 5 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).
- BIOA’s TA Score: 5 bullish, 2 bearish.
- NBIX’s TA Score: 5 bullish, 3 bearish.
Price Growth
BIOA (@Pharmaceuticals: Generic) experienced а +1.66% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +3.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.82%. For the same industry, the average monthly price growth was -9.61%, and the average quarterly price growth was +10.18%.
Reported Earning Dates
BIOA is expected to report earnings on Nov 05, 2026.
NBIX is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.82% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
BIOA and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.
| Ticker / NAME | Correlation To BIOA | 1D Price Change % | ||
|---|---|---|---|---|
| BIOA | 100% | -0.90% | ||
| UPC - BIOA | 43% Loosely correlated | +12.43% | ||
| NBIX - BIOA | 37% Loosely correlated | -0.49% | ||
| TKNO - BIOA | 26% Poorly correlated | -20.84% | ||
| HROW - BIOA | 23% Poorly correlated | +0.61% | ||
| TEVA - BIOA | 23% Poorly correlated | -0.56% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MBCE | 37.42 | 0.59 | +1.61% |
| Monarch Blue Chips Elite Index ETF (MBCE) | |||
| UXJA | 39.29 | 0.39 | +1.01% |
| FT Vest U.S. Equity Uncapped Accelerator ETF - January (UXJA) | |||
| QVOL | 95.30 | 0.74 | +0.78% |
| Infrastructure Capital Nasdaq Option Income ETF (QVOL) | |||
| BBUS | 139.51 | 0.83 | +0.60% |
| JPMorgan BetaBuilders U.S. Equity ETF (BBUS) | |||
| IBMP | 25.30 | 0.02 | +0.08% |
| iShares iBonds Dec 2027 Term Muni Bond ETF (IBMP) | |||